Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4065
Source ID: NCT00604396
Associated Drug: Insulin Detemir
Title: Safety and Efficacy of Insulin Detemir in Combination With OAD in Type 2 Diabetes
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes|Diabetes Mellitus, Type 2
Interventions: DRUG: insulin detemir|DRUG: insulin NPH
Outcome Measures: Primary: HbA1c, after 26 weeks of treatment | Secondary: Fasting plasma glucose|Within-subject variation|Incidence of total hypoglycaemic episodes|Body weight|Incidence of adverse events|Insulin antibodies
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 477
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2003-03
Completion Date: 2004-01
Results First Posted:
Last Update Posted: 2017-01-27
Locations: Novo Nordisk Investigational Site, Arlon, 6700, Belgium|Novo Nordisk Investigational Site, Gilly, 6060, Belgium|Novo Nordisk Investigational Site, Huy, 4500, Belgium|Novo Nordisk Investigational Site, Jumet, 6040, Belgium|Novo Nordisk Investigational Site, Rijeka, 51 000, Croatia|Novo Nordisk Investigational Site, Zagreb, 10 000, Croatia|Novo Nordisk Investigational Site, Hjørring, 9800, Denmark|Novo Nordisk Investigational Site, Hvidovre, 2650, Denmark|Novo Nordisk Investigational Site, Kalundborg, 4400, Denmark|Novo Nordisk Investigational Site, København S, 2300, Denmark|Novo Nordisk Investigational Site, København, 2400, Denmark|Novo Nordisk Investigational Site, Køge, 4600, Denmark|Novo Nordisk Investigational Site, Slagelse, 4200, Denmark|Novo Nordisk Investigational Site, Århus C, 8000, Denmark|Novo Nordisk Investigational Site, Amiens, France|Novo Nordisk Investigational Site, Auxerre, 89000, France|Novo Nordisk Investigational Site, Avignon, 84902, France|Novo Nordisk Investigational Site, DAX, 40107, France|Novo Nordisk Investigational Site, Evry, 91014, France|Novo Nordisk Investigational Site, Mougins, 06250, France|Novo Nordisk Investigational Site, Nanterre, 92014, France|Novo Nordisk Investigational Site, NEVERS cedex, 58033, France|Novo Nordisk Investigational Site, Rueil-Malmaison, 92501, France|Novo Nordisk Investigational Site, Valenciennes, 59322, France|Novo Nordisk Investigational Site, Venissieux, 69200, France|Novo Nordisk Investigational Site, Skopje, 1000, Macedonia, The Former Yugoslav Republic of|Novo Nordisk Investigational Site, Bekkestua, 1357, Norway|Novo Nordisk Investigational Site, Bergen, NO-5012, Norway|Novo Nordisk Investigational Site, Elverum, 2408, Norway|Novo Nordisk Investigational Site, Gjettum, 1346, Norway|Novo Nordisk Investigational Site, Gjøvik, NO-2819, Norway|Novo Nordisk Investigational Site, Jessheim, 2050, Norway|Novo Nordisk Investigational Site, Oslo, 0370, Norway|Novo Nordisk Investigational Site, Rådal, 5235, Norway|Novo Nordisk Investigational Site, Stavanger, 4011, Norway|Novo Nordisk Investigational Site, Gniewkowo, 88-140, Poland|Novo Nordisk Investigational Site, Krakow, 31-261, Poland|Novo Nordisk Investigational Site, Lodz, 90-030, Poland|Novo Nordisk Investigational Site, Lublin, 20-718, Poland|Novo Nordisk Investigational Site, Rawa Mazowiecka, 96-200, Poland|Novo Nordisk Investigational Site, Szczecin, 71-455, Poland|Novo Nordisk Investigational Site, Tychy, 43-100, Poland|Novo Nordisk Investigational Site, Warsaw, 01-809, Poland|Novo Nordisk Investigational Site, Warsaw, 01-877, Poland|Novo Nordisk Investigational Site, Warszawa, 02-097, Poland|Novo Nordisk Investigational Site, Wolomin, 05-200, Poland|Novo Nordisk Investigational Site, Zabrze, 41-800, Poland|Novo Nordisk Investigational Site, Moscow, 117036, Russian Federation|Novo Nordisk Investigational Site, Moscow, 119435, Russian Federation|Novo Nordisk Investigational Site, Moscow, 123448, Russian Federation|Novo Nordisk Investigational Site, Moscow, 127411, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, 194354, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, 198013, Russian Federation|Novo Nordisk Investigational Site, Trencin, 91171, Slovakia|Novo Nordisk Investigational Site, Falun, 791 82, Sweden|Novo Nordisk Investigational Site, Grästorp, 467 22, Sweden|Novo Nordisk Investigational Site, Kristianstad, 291 85, Sweden|Novo Nordisk Investigational Site, Linköping, 581 85, Sweden|Novo Nordisk Investigational Site, Lund, 221 85, Sweden|Novo Nordisk Investigational Site, Lund, 223 70, Sweden|Novo Nordisk Investigational Site, Trelleborg, 231 85, Sweden|Novo Nordisk Investigational Site, Umeå, 901 85, Sweden
URL: https://clinicaltrials.gov/show/NCT00604396

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress